Editas Competitor CRISPR Therapeutics Hails European Patent Decision

CRISPR Therapeutics says its IP position has been reinforced by the European Patent Office's aim to grant the University of California patent recognition covering CRISPR gene-editing for non-cellular and cellular use.

Manipulation of DNA

The European Patent Office has indicated it favors the University of California's argument that its discovery covers CRISPR use in both prokaryotic and eukaryotic systems, boosting UC's legal position and that of the companies which have licensed its genome editing patents.

UC and its commercial licensees have been fighting the Broad Institute of Cambridge, Massachusetts and its ally Editas Medicine...

More from Business

More from Scrip